linjc16/ctgov huggingface dataset:
Effect of FES of Back Muscles on Spinal Posture and Gait in Hemiplegia

Study Overview
=================
Brief Summary
-----------------
Hemiplegic patient have unbalanced posture because paralysis leads to muscle atrophy, which then causes an unbalanced alignment in the structure of spinal joints. Evaluation and therapy of postural alignment are important as early predictable factors in the overall daily function of stroke patients

Detailed Description
-----------------
To evaluate whether the application of FES of the back muscles in hemiplegic affect spinal posture and/or gait

Official Title
-----------------
Effect of FES of Back Muscles on Spinal Posture and Gait in Hemiplegia

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Other: functional electrical stimulation
* Other: kinesotaping


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20 children with c.p. hemiplegia moving and performing daily activities independently no problems in terms of verbal communication no physical and cognitive restrictions. Exclusion Criteria: Having cognitive impairment as tested by the Mini-Mental State Examination (with scores < 24) Uncontrolled hypertension (systolic blood pressure > 160 mmHg) Joint replacement Incontinence

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: study group<br>20 patient with hemiplegia | Other: functional electrical stimulation<br>* functional electrical stimulation on back muscles<br>Other: kinesotaping<br>* no intervention<br>|
| Active Comparator: control group<br>20 patient with hemiplegia | Other: functional electrical stimulation<br>* functional electrical stimulation on back muscles<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| spinal posture | 3 D assessment of spinal posture using Microsoft kinect | up to 8 weeks | 
| Balance assessment | balance assessment using Time up and go test TUG high risk (>13.5 seconds): ____ None/low/moderate: (<13.5 seconds) and Berg scale normal score for elderly (45:56) | up to 8 weeks |
Enteral Glutamine in Neurologically-injured Patients

Study Overview
=================
Brief Summary
-----------------
Nutrition is an important part of the recovery process after having a head injury so that subjects can gain strength and fight off infection. Liquid nutrition formulas are often given to patients through a tube that has been placed into the intestines for feeding when they are unable to eat on their own. Some reports suggest that nutrition with extra amounts of the amino acid called glutamine may decrease infections and hospital stay in severely injured patients.The purpose of this study is to evaluate if giving extra amounts of an amino acid called glutamine with liquid nutrition formulas will decrease the risk of infection and length of stay in the intensive care unit after having a head injury.

Official Title
-----------------
Randomized, Placebo-controlled Clinical Trial of Enteral Glutamine Supplementation in Neurologically-injured Patients

Conditions
-----------------
Neurologic Injury, Traumatic Brain Injury

Intervention / Treatment
-----------------
* Dietary Supplement: Enteral glutamine powder
* Other: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males Nonpregnant females Aged 18-75 years old Glasgow Coma Scores of 3-12 Injury Severity Scores greater than or equal to 20 Requiring enteral nutrition for a minimum of 5 days Exclusion Criteria: Documented hepatic dysfunction Acute renal failure (creatinine clearance < 15 mL/min) Gastrointestinal malabsorptive disorder Infection at time of admission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Nutritional supplement | Dietary Supplement: Enteral glutamine powder<br>* nutritional supplement<br>|
| Placebo Comparator: 2<br>placebo | Other: placebo<br>* placebo control<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nosocomial infections |  | throughout study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Multiple organ dysfunction syndrome |  | throughout the study | 
| Nutritional outcome parameters |  | throughout the study |
The Effect of Quercetin in Sarcoidosis

Study Overview
=================
Brief Summary
-----------------
The exact cause of the chronic lung disease sarcoidosis is still unknown. Consequently, a complete efficacious treatment is still not available. Earlier studies indicate an important key role for oxidative stress, i.e. an imbalance between the production of and the protection against ROS, in the etiology of sarcoidosis. Antioxidants, needed for protection against ROS, are indeed lower in sarcoidosis. Therefore, antioxidant therapy to strengthen the reduced antioxidant defense might be efficacious in sarcoidosis treatment. Since ROS are also capable of initiating and mediating inflammation, antioxidant therapy might also mitigate the elevated inflammation that occurs in sarcoidosis. The flavonoid quercetin possesses both anti-oxidative and anti-inflammatory capacities and might therefore serve as a good candidate for antioxidant therapy in sarcoidosis. Therefore, the aim of the present study is to determine the effect of quercetin supplementation in sarcoidosis patients on markers of both oxidative stress and inflammation.

Official Title
-----------------
The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis

Conditions
-----------------
Sarcoidosis

Intervention / Treatment
-----------------
* Dietary Supplement: quercetin
* Other: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of sarcoidosis with emphasize on pulmonary sarcoidosis no smoking no treatment Exclusion Criteria: clinical diagnosis (and treatment) of other diseases symptoms of sarcoidosis in other organs besides the lung use of food supplements or vitamins
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br>placebo | Other: placebo<br> <br> |
| Active Comparator: 2<br>quercetin (food supplement) | Dietary Supplement: quercetin<br>* 1000 mg quercetin within 24 hours<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| antioxidant status after 24 hours |  | 24 hours | 
| inflammatory status after 24 hours |  | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| plasma quercetin concentration after 24 hours |  | 24 hours | 
| plasma malondialdehyde (MDA) levels after 24 hours |  | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
inflammation, sarcoidosis, quercetin, supplementation, oxidative stress
A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control

Study Overview
=================
Brief Summary
-----------------
To determine the effect on glycemic control and lipid parameters of the 2.5 and 5 mg. doses of BMS-298585 in drug naive subjects with Type 2 diabetes as an adjunct to diet and exercise.

Official Title
-----------------
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control

Conditions
-----------------
Diabetes, Type 2

Intervention / Treatment
-----------------
* Drug: Muraglitazar


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with Type 2 diabetes Drug Naive HbA1c >= 7.0% and <= 10.0% Body Mass Index <= 41 kg/m2 Serum TG <= 600 mg/dL Exclusion Criteria: Symptomatic Type 2 diabetes History of bladder cancer History of Myocardial Infarction (MI), coronary angioplasty or bypass grafts, valvular disease or repair, unstable angina pectoris, Transient Ischemic Attach (TIA), or Cerebrovascular Accident (CVA) within 6 months, congestive heart failure (NYHA Class II and IV), uncontrolled hypertension, history of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease or endocrine disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Muraglitazar|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in HbA1c from baseline to Week 24 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes achieved from baseline in FPG after 24 weeks. Changes achieved from baseline in 3 hour post-prandial AUC for glucose and insulin levels after 24 weeks vs. placebo. |  |  |
Clinical Study on Screening of Nursing Evaluation Indicators of Stroke Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to use Delphi method to screen the nursing observation indexes of patients with stroke, and to screen the sensitive indexes with high correlation with the severity of stroke.It is used to guide nursing staff to observe the nursing of patients with cerebral apoplexy.

Official Title
-----------------
Convenience Sampling，Clinical Study on Screening of Nursing Evaluation Indicators of Stroke Patients

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Other: Nursing observation indexes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ①according to the diagnostic criteria which was revisied in 1996 at the fourth national cerebrovascular disease conference,Patients were diagnosed with cerebral apoplexy through computerized tomographic scanning or Magnetic Resonance Imaging examination. ②Patients who volunteer to participate in the study and Sign the consent form. Exclusion Criteria: ①Patients With other serious diseases, such as tumor, grade 2 or above of cardiac function. ②Had a history of mental illnes.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| stroke patients；neurologic impairment<br>It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy. | Other: Nursing observation indexes<br>* It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| construct a nursing evaluation system for stroke patients | The nursing indexes of patients with cerebral apoplexy were selected. The nursing observation indexes of stroke patients were digitized and an electronic nursing evaluation sheet was formed. | October 1st, 2017 - October 1st, 2018 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stroke；nursing assessment；condition of a patient；deterioration；
Effectiveness of Chlorhexidine Wipe for Prevention of Multidrug-resistant Organisms in Intensive Care Unit Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine 2% chlorhexidine wipes are effective in preventing of colonization of multi-drug resistant bacteria in intensive care unit patients.

Detailed Description
-----------------
The purpose of this study is to evaluate the usefulness of bathing with chlorhexidine wipe to reduce the risks of multidrug resistant bacteria acquisition and hospital-acquired bloodstream infection among ICU patients

Official Title
-----------------
Effectiveness of Chlorhexidine Wipe for Prevention of Multidrug-resistant Organisms in Intensive Care Unit Patients

Conditions
-----------------
Antibiotic Resistant Infection

Intervention / Treatment
-----------------
* Drug: 2% chlorhexidine wipe
* Drug: Soap


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Admission in critical care unit eg. ICU, respiratory care unit, Cardiac care unit with in 24 hours Expected duration of critical care unit admission > 48 hours Exclusion Criteria: History of chlorhexidine allergy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Soap bathing<br>ICU patients will be bathing with soap at least once daily | Drug: Soap<br>* The ICU patients will be bathing with Soap<br>* Other names: Control soap;|
| Experimental: 2% chlorhexidine wipes<br>Use 2% chlorhexidine wipes to clean the patient at least once daily | Drug: 2% chlorhexidine wipe<br>* The ICU patients will be bathing with 2% chlorhexidine wipe<br>* Other names: chlorhexidine wipe;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The overall rate of Multidrug resistant bacteria acquisition at 7 days after received 2% chlorhexidine wipe bathing versus with soap bathing | 7 days after received 2% chlorhexidine wipes,the microbiology laboratory will process surveillance specimens using either standard culture-based at both nostrils, axillar, groins, rectum | 7 days after recieved 2% chlorhexidine wipes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The overall rate of hospital-acquired bloodstream infections per 1000 patient-days with chlorhexidine wipe bathing versus with soap bathing |  | 48 hours after recieved 2% chlorhexidine wipes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colonization
The Genetic Basis for Vulnerability to Substance Abuse

Study Overview
=================
Brief Summary
-----------------
This investigation seeks to better define the genetic basis for vulnerability to substance abuse.

Detailed Description
-----------------
Dopamine (DA), a neurotransmitter helping to mediate reward and reinforcement, has been putatively linked to the development of substance abuse, alcohol abuse, and alcoholism. Identification of specific vulnerability-association alleles for receptors, other molecules within the reward mediating system, and other genes that may predispose individuals to the development of such disorders is the goal of the study. This investigation will help elucidate the genetic underpinnings of substance abuse, potentially leading to the improved methods to diagnose those at risk and to help develop better therapeutic interventions.

Official Title
-----------------
Allelic Linkage in Substance Abuse

Conditions
-----------------
Substance Abuse

Intervention / Treatment
-----------------
* Procedure: Blood draw


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Substance abusers Allow for blood draw Exclusion Criteria: Cognitively impaired

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Blood draw|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Substance abuse
Positioning During Colonoscopy

Study Overview
=================
Brief Summary
-----------------
Colonoscopy is the gold standard investigation in the screening of colorectal neoplasms. The investigators hypothesise that visualisation of the colonic mucosa on extubation may be improved by changing patient position as follows: left lateral position for the right colon, supine for the transverse colon and right lateral position for the left colon(fixed positioning). The investigators aim to validate our hypothesis by performing a randomised control study, comparing mucosal visualisation in patients placed in the 'routine' positions at the discretion of the endoscopist with visualisation in those placed in the above described positions. The hypothesis is that fixed positioning confers an advantage.

Official Title
-----------------
Does Patient Position During Extubation at Colonoscopy Influence the Quality of Mucosal Visualisation?

Conditions
-----------------
Colonic Polyps

Intervention / Treatment
-----------------
* Procedure: Colonoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients requiring colonoscopy Exclusion Criteria: Polyp surveillance Cancer surveillance Infirmity Pregnancy Colectomy Poor tolerance Failed colonoscopy Poor bowel preparation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 'Free' positioning withdrawal<br>Withdrawal of the colonoscope with the patient positioned at the discretion of the endoscopist | Procedure: Colonoscopy<br>* Recording of colonoscopic extubation<br>|
| Experimental: 'Fixed' position withdrawal<br>Patient positioned in the left lateral position to visualise the caecum, ascending colon and hepatic flexure; supine to visualise the transverse colon; and in the right lateral position to visualise the splenic flexure, descending colon and the sigmoid colon | Procedure: Colonoscopy<br>* Recording of colonoscopic extubation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mucosal visualisation | Made by video assessment of colonoscopic withdrawal | 3 months | 
| Luminal distension |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colonoscopy, Positioning in colonoscopy, Quality control
Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue

Study Overview
=================
Brief Summary
-----------------
Breast cancer tissue is collected from women undergoing scheduled surgery for breast cancer. The tissue specimen are analyzed by MR spectroscopy. After MR, the intact tissue specimen can be analyzed by other methods, such as histopathology. The MR spectral profiles are compared to clinical findings such as the patients diagnosis, lymph node status and tumor size.

Official Title
-----------------
HR MAS MR Spectroscopy of Breast Cancer Tissue

Conditions
-----------------
Breast Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Palpable breast cancer lesion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MRimage of breast cancer tissue |  | 0 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Magnetic Resonance Spectroscopy
Disability, Perceived Social Support and Quality of Life in Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
The World Health Organization International Classification of Functioning, Disability and Health has shown that the environment can play a major role in patients' disability, and hence in their quality of life. This study considers social dimensions of quality of life, particularly family as well as social and professional networks.

Conditions
-----------------
Multiple Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: multiples sclerosis, according to McDonald's criteria Exclusion Criteria: lack of French language proficiency severe cognitive impairment severe aphasia substance addiction psychiatric troubles (except for treated major depression) other severe neurologic or somatic disease pregnant or breast feeding patient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| statistical association between perceived social support and quality of life |  | immediate |